Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term semaglutide effects on diabetic retinopathy in adults with type 2 diabetes
MOH_2019-03-06_004916Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) and diabetic retinopathy (DR) comparing Semaglutide plus usual care with Placebo plus usual care (2 arms). Started Feb 2019; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic retinopathy (DR)
Beyond the preview
Go deeper on MOH_2019-03-06_004916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-06_004916.